Anti-HIV-1 gp120 Reference Antibody (Teropavimab, RUO)

Description: Teropavimab (BS11484) is a research-grade recombinant antibody targeting gp120/Glycoprotein 120. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Humanized
Isotype: IgG1-kappa
Species reactivity: Humanimmunodeficiencyvirus1(HIV-1)
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 30 mM histidine pH5.8,10% sucrose, 0.02% Tween80
Concentration: 1.04mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: gp120/Glycoprotein120
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: 3BNC117-LS,GS-5423CAS:2417213-72-8
Background: Envelope glycoprotein gp160 (gp120/Glycoprotein 120) is a ~96 kDa protein. Envelope glycoprotein gp160: Oligomerizes in the host endoplasmic reticulum into predominantly trimers. In a second time, gp160 transits in the host Golgi, where glycosylation is completed. The precursor is then proteolytically cleaved in the trans-Golgi and thereby activated by cellular furin or furin-like proteases to produce gp120 and gp41.
Note: For research use only. Not suitable for clinical or therapeutic use.